Valuation: Santhera Pharmaceuticals Holding AG

Market Cap 223M 273M 240M 205M 385M 26.31B 391M 2.65B 1.04B 12.93B 1.03B 1B 44.72B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 251M 307M 270M 230M 433M 29.58B 439M 2.98B 1.16B 14.54B 1.15B 1.13B 50.27B EV / Sales 2026 *
2.65x
EV / Sales 2027 * 2.12x
Free-Float
81.19%
Yield 2026 *
-
Yield 2027 * -
1 day+0.95%
1 week-3.37%
Current month-5.10%
1 month-6.64%
3 months-12.04%
6 months+7.66%
Current year+18.25%
1 week 14.48
Extreme 14.48
15.46
1 month 14.42
Extreme 14.42
16.3
Current year 11.7
Extreme 11.7
18.84
1 year 9.38
Extreme 9.38
18.84
3 years 7.14
Extreme 7.14
18.84
5 years 5
Extreme 5
26.6
10 years 5
Extreme 5
820
Manager TitleAgeSince
Chief Executive Officer 50 15/07/2026
Director of Finance/CFO 51 24/02/2025
Chief Operating Officer 55 01/09/2022
Director TitleAgeSince
Chairman 64 30/06/2022
Director/Board Member 58 04/04/2017
Director/Board Member 47 27/06/2023
Date Insider Type Main position Quantity % Market Cap.
1/22/24 A Buy 30,228 0.2396%
7/6/23 A Buy 2,000 0.0016%
1/11/22 A Buy 30,000 0.0549%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-3.37%+7.35%+84.86% 273M
+0.45%+2.80%+55.83%+20.48% 324B
-0.07%+2.09%+22.76%-11.68% 68.88B
+1.35%+5.29%+39.41%+91.60% 9.72B
+0.93%-1.38%+1.71%-4.10% 8.37B
+1.13%+1.51%-20.98%-4.73% 4.32B
-4.00%+0.71%-7.10%+12.39% 3.62B
+4.90%+5.79%-39.25%+19.34% 3.83B
-2.10%-3.83%+40.64%+53.74% 2.68B
-4.07%-2.45%-3.76%-17.52% 2.04B
Average -0.05%+0.78%+9.66%+24.44% 42.75B
Weighted average by Cap. +0.37%+2.17%+46.50%+16.17%

Financials

2026 *2027 *
Net sales 94.7M 116M 102M 86.9M 163M 11.17B 166M 1.12B 439M 5.49B 435M 426M 18.98B 116M 141M 124M 106M 199M 13.62B 202M 1.37B 536M 6.7B 531M 520M 23.16B
Net income - -
Net Debt 27.7M 33.91M 29.79M 25.42M 47.76M 3.27B 48.5M 329M 129M 1.61B 127M 125M 5.55B 21.4M 26.2M 23.01M 19.64M 36.9M 2.52B 37.47M 254M 99.28M 1.24B 98.35M 96.23M 4.29B
Logo Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Employees
94
Date Price Change Volume
24/07/26 CHF 14.90 +0.95% 19,618
23/07/26 CHF 14.76 -1.34% 44,077
22/07/26 CHF 14.96 -1.19% 31,383
21/07/26 CHF 15.14 +0.66% 42,194
20/07/26 CHF 15.04 -2.46% 48,321
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
14.90CHF
Average target price
27.50CHF
Spread / Average Target
+84.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANN Stock